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A Humanized Stromal Bed Is Required for
Engraftment of Isolated Human Primary Squamous
Cell Carcinoma Cells in Immunocompromised Mice
Girish K. Patel1, Carole L. Yee1, Stuart H. Yuspa2 and Jonathan C. Vogel1
Epithelial cancers are the most common malignancies and the greatest cause of cancer mortality worldwide.
The incidence of keratinocyte-derived (non-melanoma) skin cancers is increasing rapidly. Despite access to
abundant tumor tissue and ease of observation, acceptance of non-melanoma skin cancers as model
carcinomas has been hindered by the lack of a reliable xenograft model. Herein we describe conditions that
allow routine xeno-engraftment of primary human squamous cell carcinoma (SCCa) cells. Tumor development
required creation of an appropriate stromal bed before xenografting tumor tissue onto the backs of athymic
nude mice. We also demonstrate that the stromal bed must be ‘‘humanized’’ if primary human SCCa is to be
propagated from cell suspensions. SCCa xenografts recapitulated the histological grade and phenotype of
the original tumors with considerable fidelity, even after serial passage, irrespective of the histological grade
of the primary human SCCa. This model, which to our knowledge is previously unreported, can be used
for drug testing, as well as for studies that are relevant to the biology of primary human SCCa and other
epithelial cancers.
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INTRODUCTION
Cancers of epithelial tissues (skin, stomach, lung, breast,
prostate, and colon) approximately account for 85% of all
cancers and 75% of all cancer-related deaths in the United
States and worldwide (Altekruse et al., 2009; Ferlay et al.,
2010). Among carcinomas, although not included in these
cancer statistics because of their relatively low mortality,
the incidence of non-melanoma skin cancer (basal cell
carcinoma and squamous cell carcinoma (SCCa)) is rising
faster than all other cancers (Green et al., 1996; Buettner and
Raasch, 1998; Holme et al., 2000; Diepgen and Mahler,
2002; Christenson et al., 2005; Benton et al., 2008).
Currently, non-melanoma skin cancers are the most frequent
of all cancers and affect 1 million Americans per year, 250,000
of whom have SCCa (http://www.cancer.org/Cancer/SkinCancer-
BasalandSquamousCell/OverviewGuide/skin-cancer-basal-
and-squamous-cell-overview-key-statisticsr). Despite the high
incidence and ease of observation, the study of primary human
SCCa as a model of epithelial cancer has been hindered by the
lack of reproducible in vivo tumor tissue growth assays.
Although the genetic basis of human SCCa has not been
completely characterized and likely involves a number of
different alterations (Boukamp, 2005), B50% of all SCCas
harbor a UV light-induced p53 mutation in one or both
alleles (Brash et al., 1991; Ziegler et al., 1994). In addition, as
overexpression of the RAS signaling pathway is observed in
75% of all SCCas, RAS likely has a critical role in SCCa
initiation and maintenance (Dajee et al., 2003). Previously, it
has been suggested that a minimal set of alterations,
including RAS activation and NF-kB pathway inactivation
or upregulation of cyclin-dependent kinase 4, are sufficient to
transform normal human keratinocytes resulting in SCCa-like
tumors in a subcutaneous xenograft model (Dajee et al.,
2003; Ortiz-Urda et al., 2005).
Primary human skin (either intact or as reconstituted
human skin equivalents) can be successfully grafted onto the
backs of immunocompromised mice (Pouliot et al., 2002;
Guerret et al., 2003). These grafts retain many features of
normal human skin: structure (Bohnert et al., 1989; Kim et al.,
1992), epidermal differentiation (Demarchez et al., 1986),
and function (Demarchez et al., 1986; Kim et al., 1992).
However, establishing primary human SCCa xenografts has
been proved to be difficult. Most successful xenografts of
human SCCa involve cell lines. Rheinwald and Beckett
(1981) reported two primary human cutaneous SCCas and
four orally derived SCCas from cells that had been passaged
in tissue culture before successful grafting onto athymic
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nude mice. Intriguingly, reproducible tumor growth required
implantation of X3106 cultured SCCa cells. Similarly, the
Fusenig laboratory reported engraftment of two poorly
differentiated primary human SCCas from tissue-cultured
passaged cells onto athymic nude mice (Boukamp et al.,
1982; Tilgen et al., 1983). Independent of these early
successes and despite the subsequent availability of addi-
tionally immunocompromised mouse strains that have
allowed successful xenografts of other tumor types, xeno-
engraftment of primary human SCCa remains challenging
(Takizawa et al., 1997).
Orthotopic xenograft models are essential for investigation
of tumor biology, notably in the identification of tumor-
initiating cell subpopulations, as well as for drug testing. The
lack of standardized in vivo models that allow establishment
and propagation of SCCa, and characterization of tumor-
initiating cells in SCCa, has been a significant problem. To
address this issue, we developed a reliable in vivo orthotopic
xenograft assay that allows routine growth of tumors from
directly implanted primary human SCCa tissue and cell
suspensions.
RESULTS
Orthotopic primary human SCCa xenografts rarely engraft
Normal skin can be xenografted onto immunocompromised
mouse strains, either as intact tissue or alternatively recon-
stituted human skin equivalents (Demarchez et al., 1986;
Bohnert et al., 1989; Kim et al., 1992; Pouliot et al., 2002;
Guerret et al., 2003). To develop an in vivo assay for primary
human SCCa, we first attempted tumor growth by xenograft-
ing intact tumor tissue (0.5 cm3) in which epithelial–stromal
relationships are maintained onto various immunocompro-
mised mice. Despite using nude, severe combined immuno-
deficient (SCID)-beige, and non-obese diabetic (NOD)-SCID
mice strains, onto which we subcutaneously implanted 22
different primary human SCCas, reproducible tumor growth
was not achieved (row 1, Table 1). Although surprising, our
observation is consistent with the literature (Rheinwald and
Beckett, 1981; Takizawa et al., 1997).
Creation of a stromal bed facilitates primary human SCCa
xenograft growth in vivo
We hypothesized that as primary human SCCas are highly
vascularized tumors, insufficient blood supply at the sub-
cutaneous graft site might be responsible for graft failure. To
facilitate xenograft engraftment and to increase vascularity,
we induced a stromal reaction by first implanting either a
subcutaneous glass disc (Roop et al., 1986) or Gelfoam
dressing (Zeamari et al., 2004) 2 weeks before the intact
tumor tissue xenograft (Figure 1a and b). We used athymic
nude and SCID-beige mouse strains as these had allowed the
growth of a single clinically aggressive SCCa. Of the 25
different primary human SCCa tissue xenografts, 22 demon-
strated tumor growth as confirmed by serial tumor measure-
ments and subsequent histology (Figure 1c and row 2,
Table 1). All histological grades of primary human SCCa
successfully engrafted and grew, including 4 of 6 poorly
differentiated SCCas, 7 of 7 moderately differentiated SCCas,
and 11 of 12 well-differentiated SCCas. All tumors main-
tained their original morphology in vivo, including large
well-differentiated tumors (Figure 1d). The growth rates of
human SCCa xenografts were consistent with the relatively
slow growth rate of in situ SCCa in patients (Figure 1c).
Intriguingly, xenograft growth was observed in athymic nude,
but not in more immunocompromised SCID-beige, mice.
None of the four different SCCa samples that grew as
xenografts in athymic nude mice grew in SCID-beige mice,
despite simultaneous engraftment using the identical experi-
mental protocol. Although the number of SCID-beige mice is
low, one would have expected at least an equal, if not
greater, rate of graft takes in the more immunocompromised
mice. Thus, primary human SCCa xenograft growth was not
achievable in more severely immunocompromised mice
strains, and was clearly dependent upon the prior creation
of a stromal reaction.
To confirm that xenograft tumors contained primary
human SCCa epithelial cells, we stained tumor xenograft
sections with antibodies to human HLA antigens, murine
MHC class 1 antigens (Figure 2a), human cytokeratins
(Figure 2b), and human p53 (Figure 2c). The p53 antibody
Table 1. Development of an in vivo SCCa model
Xenograft tumor frequency in different mouse strains
SCCa tumor xenograft Graft site preparation Nude SCID-beige NOD-SCID
Intact tumor tissue None 1 of 22 1 of 5 0 of 5
Intact tumor tissue Creation of a stromal bed 22 of 25 0 of 4 ND
Minced tumor tissue Creation of a stromal bed 3 of 3 ND ND
Single-cell suspension Creation of a stromal bed 3 of 24 ND ND
Single-cell suspension with 106
primary human fibroblasts
Creation of a stromal bed 0 of 8 ND ND
Single-cell suspension with 106
primary human fibroblasts
Creation of a ‘‘humanized’’ stromal bed 28 of 29 ND 0 of 4
Abbreviations: ND, not done; NOD, non-obese diabetic; SCCa, squamous cell carcinoma; SCID, severe combined immunodeficient.
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Figure 1. Creation of a squamous cell carcinoma (SCCa) in vivo xenograft model that can accurately recapitulate and propagate human SCCa from intact
tumor tissue. (a) Successful engraftment of primary human SCCa tissue required before creation of a stromal bed, into which the tissue is implanted after
14 days. After 12 weeks, tumor growth was determined by histological sampling of all xenograft sites. (b) Hematoxylin and eosin-stained sections of
athymic nude mouse skin demonstrate a fibrovascular proliferation following subcutaneous implantation of either a glass disc or Gelfoam dressing for
2 weeks. (c) Tumor growth after implantation of intact SCCa tissue of similar size. (d) Xenograft tumors that developed from intact, primary human SCCa
preserved the original tumor morphology. Bar¼ 100mm.
Human HLA + murine MHC
Original SCCa Primary xenograft Secondary xenograft
Human HLA + human mutant p53Human cytokeratin
Figure 2. Xenografts express human markers and can be passaged in vivo. Primary human squamous cell carcinoma (SCCa)-derived xenograft tumors expressed
human (a) HLA antigen, (b) cytokeratin, and (c) nuclear accumulation of mutant p53. Respective isotype controls are shown in panels underneath. Xenograft
tumor stroma was predominantly replaced by murine cells that expressed murine major histocompatibility complex (MHC) class 1. Nonspecific staining was
observed within the dead squamous accumulations. (d) Recreation of the original tumor morphology upon in vivo serial passage of the previously xenografted
tumor. Histology after 12 weeks was similar to the original and primary xenograft tumors. Bar¼ 100mm.
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clone used binds to the DNA-binding domain and specifically
recognizes the mutated protein. After 12 weeks, most tumor
stroma comprised murine cells. Primary human SCCa xeno-
grafts retained human HLA, keratin, and mutant p53 protein
expression, demonstrating the survival and growth of primary
human SCCa keratinocytes. The xenograft tumors were also
amenable to serial passage (Figure 2d). We concluded that
athymic nude mice supported subcutaneous primary human
SCCa xenografts, after creation of fibrovascular beds by
implantation of either glass discs or Gelfoam dressings.
Primary human SCCa-derived cell suspensions require human
fibroblasts to form a xenograft
We next attempted to adapt the in vivo model that we had
created for intact tumor tissue to allow tumor growth in vivo
from primary human SCCa-derived cell suspensions. First, we
demonstrated that tumor xenograft growth was possible in
three of three SCCa xenografts with fragments of tumor tissue
(Figure 3a–c, row 3, Table 1). To derive single-SCCa-cell
suspensions, we modified the enzymatic digestion protocol
for normal skin dissociation (Figure 3d and e), resulting in
between 30 and 70% cell viability as assessed by FACS
analysis (Figure 3f). However, when we attempted to initiate
SCCa tumor growth by xenografting unsorted cell suspen-
sions derived from human SCCas, we achieved growth in
only 3 of 24 SCCa cell suspension xenografts after4106 cells
were resuspended in Matrigel and injected into the sub-
cutaneous fibrovascular bed created in athymic nude mice
(row 4, Table 1). To improve the proximity of stromal and
tumor cells, we next supplemented primary human SCCa cell
suspensions with an additional 106 primary normal human or
SCCa-associated fibroblasts before implantation. With this
approach, we achieved no tumor growth from eight different
primary human SCCas (row 5, Table 1); however, we did not
attempt implantation with greater numbers of fibroblasts.
As success in xenografting, primary human breast cancer
cells required cleared murine mammary fat pads to be first
‘‘humanized’’ by the preimplantation of human fibroblasts
(Kuperwasser et al., 2004), we hypothesized that primary
human SCCa xenografts from single-cell suspensions might
also require ‘‘humanization’’. Successful and reproducible
xenografts of human SCCa cell suspensions were ultimately
achieved when large numbers of normal human fibroblasts
were used to ‘‘humanize’’ xenograft recipient sites. One
million (106) primary normal human fibroblasts were first
suspended in Matrigel and implanted with the glass disc or
Gelfoam dressing. After 14 days, SCCa xenograft cell
suspensions were co-injected with an additional 106 primary
human normal fibroblasts suspended in Matrigel into the
prepared xenograft sites (Figure 4a). This approach yielded 28
successful xenograft tumors in 29 attempts (Table 1) using
cell suspensions derived from 29 different primary human
SCCas: 16 well-differentiated SCCas, 7 moderately differ-
entiated SCCas, and 6 poorly differentiated SCCas. The
histological patterns of these xenograft tumors recapitulated
the original primary human SCCa histologies irrespective of
the histological classification of the tumors (Figure 4b). For
success, a minimum number of SCCa cells were required
such that xenograft success was assured ifX3106 unsorted
primary human SCCa cells were xenografted. Tumor growth
was not reproducible with xenografts containing o3106
unsorted primary human SCCas independent of the histolog-
ical grade of the original tumor (Figure 4c). Robust xenograft
growth was observed in athymic nude mice, and not in the
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Figure 3. Squamous cell carcinoma (SCCa) mechanical dissociation and generation of a single-cell suspension. (a) Primary human SCCa was (b) mechanically
dissociated using surgical scissors, and (c) the minced tumor tissue was then implanted onto wound beds created by either a glass disc or Gelfoam dressing
that had been implanted for 14 days in the athymic nude mice. Shown is a typical tumor after 12 weeks. (d) Cell suspensions were created by additional
enzymatic dissociation so that few cells remained in the remnant tissue. (e) Tumor cells could be labeled with a human pancytokeratin antibody and
(f) approximately 70% of the tumor-dissociated cells were viable, as assessed by FACS. Bars¼100 mm.
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more immunocompromised NOD-SCID strain (row 6, Table 1),
in 0/4 attempts. Primary human SCCa xenograft tumors could
also be serially passaged into new athymic mice as cell
suspensions (Figure 4d). Hence, we successfully created an
orthotopic in vivo xenograft model using primary human SCCa
cell suspensions that reproducibly recreated the original tumor
phenotype, independent of the original histological grade.
DISCUSSION
Herein we describe an in vivo xenograft model for primary
human SCCas using intact tumor tissue and cell suspensions
in which in vivo tumor growth is reliable and recreates the
original tumor hierarchical architecture, irrespective of the
SCCa histological grade. In contrast to previously described
models, in vitro passage was not required and primary tumor
tissue or cell suspensions could be directly implanted. The
high frequency and relative ease with which primary human
SCCa tissue can be accessed, combined with the simplicity of
this model, will facilitate the study of primary human
epithelial cancer growth and drug testing. As in vivo growth
can be assured with implantation of primary human SCCa
cells, this assay can also be used for the study of potential
tumor-initiating cell populations.
Because no standardized assay has been established for
growing primary human cutaneous SCCa xenografts, we
describe our extensive efforts to develop an efficient in vivo
xenograft mouse model in some detail. In our model, creation
of a fibrovascular stromal bed by preimplantation of glass
discs or Gelfoam dressings was critical, suggesting the
relative importance of a well-developed tumor niche
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Figure 4. Xenografts can accurately recapitulate and propagate human squamous cell carcinoma (SCCa) from cell suspensions. (a) Schematic. (b) SCCa
xenografts from cell suspensions recreated the original tumor morphology (c) with no difference in xenograft growth based on the original tumor
histological grade. Xenograft success was only dependent upon the number of tumor cells implanted and (d) harvested tumor tissue could be dissociated
and successfully implanted into naive athymic nude mice. Bar¼ 100mm.
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environment. These approaches were adapted from previous
models for murine SCCa (Roop et al., 1986) and peritoneal
metastases (Zeamari et al., 2004), respectively, in which
enhanced efficiency of tumor take was demonstrated. Like-
wise, in vivo growth from primary human SCCa cell
suspensions required co-implantation of 106 primary human
fibroblasts prior to, and along with, human cells derived from
SCCa. Previously, the ‘‘humanization’’ of murine stroma was
found to be necessary for successful human breast cancer
xenografts (Kuperwasser et al., 2004). The requirement for
preimplanted human stromal cells is not well understood, as
there is abundant vascularization and murine stroma in place
even in the absence of human cells.
We were surprised that the success rate for establishing
human SCCa xenografts was consistently higher in athymic
nude mice than in more immunocompromised mice, includ-
ing SCID-beige and NOD-SCID mice, although all mice
developed a fibrovascular stroma. Athymic nude mice retain
some residual immunity with functional NK cells, but when
attempting to xenograft tumor pieces after the creation of a
stromal bed, the administration of NK neutralizing antibody
did not hinder nor enhance tumor growth (n¼3). Athymic
nude mice also retain functional B lymphocytes, suggesting
that this could facilitate tumor growth. Interestingly, the
paradoxical role of both the adaptive and innate immune
responses, particularly B lymphocytes, in facilitating mouse
SCCa growth has been previously noted (Clevers, 2004; De
Visser et al., 2006; Karin, 2006), and SCCa growth is observed
in inflamed human skin (e.g., chronic wounds, burn injury,
discoid lupus erythematosus, lichen sclerosus, lichen planus,
hidradenitis supprativa, and lupus vulgaris; Alam and Ratner,
2001). Thus, the reactive tissue milieu in the prepared graft site
may have been more inflammatory in the athymic immuno-
deficient nude mice recipients and facilitated SCCa growth (de
Visser et al., 2005). However, patients receiving immunosup-
pressants for the management of renal transplants are at greater
risk for developing clinically aggressive SCCa once tumors
have been established. The development of a SCCa in an
in vivo xenograft model using athymic nude mice is consistent
with what is known about the role of inflammation in the
pathogenesis of SCCa and the promoting effect of immuno-
deficiency. SCCa xenografts grew slowly and none of these
tumors metastasized or were lethal within 12 weeks in vivo,
consistent with the SCCa clinical phenotype in patients.
In conclusion, we have created a simple, reliable in vivo
xenograft model for primary human SCCa. This assay will be
widely applicable for drug testing, as well as for studies to
elucidate the biology of primary human SCCa and other
epithelial cancers.
MATERIALS AND METHODS
Immunofluorescence
Immunofluorescence was performed using standard techni-
ques with the following primary antibodies: pancytokeratin
(Dako, Via Real Carpinteria, CA), Mouse MHC class I (AbD
Serotec, clone 2G5, Raleigh, NC), Human HLA (AbD
Serotec, clone YTH 862.2), and mutant p53 (Calbiochem,
clone Pab240, Gibbstown, NJ).
For cytospin analysis, normal human skin keratinocytes, RS4
lymphocyte cells (ATCC), or SCCa single cells were washed
and resuspended in phosphate-buffered saline at a concentra-
tion of 105 cells per ml. Aliquots (100ml) of cells were added to
each slide cytofunnel (Shandon, Thermo Scientific, Pittsburgh,
PA), spun at 800 r.p.m. for 5minutes in a cytocentrifuge
(Shandon Cytospin 2 cytocentrifuge, Pittsburgh, PA), fixed in
acetone, and labeled with a pancytokeratin antibody as above.
Cell preparation
Normal foreskins and human SCCa were obtained after
institutional review board approval of experiments, after
obtaining written, informed patient consent, and in accor-
dance with the Declaration of Helsinki Principles. Tumor
tissue was mechanically dissociated, and then incubated for
2 hours at 37 1C in a 100-ml sterile conical flask containing
medium 199 with 200 unitsml1 Dispase (BD Biosciences,
San Diego, CA) and 200unitsml1 Ultrapure Collagenase
Type III (Sigma, St Louis, MO) with stirring on a magnetic
stirring plate in a tissue culture CO2 incubator. The semi-
dissociated mixture was pipetted into sterile 50ml tubes, and
after centrifugation at 200 g for 5minutes supernatants were
discarded. The remaining tissue was then incubated at 37 1C
for 5minutes with 0.05% trypsin with EDTA. Tissue remnants
were removed from cell suspensions by filtration through a
40-mm cell strainer.
Flow cytometry
Samples were assessed using a FACSCalibur flow cytometer
(BD Biosciences) and mouse flurochrome-conjugated IgG
subtype isotype controls (BD Pharmingen, San Diego, CA).
A live cell gate was created using 7-Amino-Actinomycin D
(BD Pharmingen) to label dead cells.
Transplantation of human SCCa cell suspensions
Athymic nude homozygous foxn1nu (Jackson Laboratory, Bar
Harbor, ME), SCID-beige, and NOD-SCID (Taconics, Rock-
ville, MD) mice were housed and used under conditions
approved by the Animal Care and Use Committee at the
National Cancer Institute. Mice were anesthetized and either
Gelfoam dressing (Johnson & Johnson, New Brunswick, NJ) or
sterilized glass discs were implanted into the dorsal sub-
cutaneous space, together with 106 primary human fibroblasts
suspended in 100ml of Matrigel (BD Biosciences) for single-
cell suspension experiments, and wounds were closed with
surgical staples (Mikron, Pittsburgh, PA). After 14 days, mice
were anesthetized, glass discs were removed, and SCCa cells
that had been suspended in 100ml of Matrigel were injected
into the subcutaneous space or alternatively into the in situ
Gelfoam dressing. After 12 weeks, mice were killed via CO2
inhalation, and tumors were removed for analysis.
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